Dare Bioscience Investor Presentation Deck
January 2020 - Bayer, which markets the
$1 billion Mirena contraceptive franchise,
and Daré announced the execution of a
license agreement under which Bayer
may commercialize Ovaprene
investigational contraceptive in the US
once approved by FDA.
BAYER
OvapreneⓇ - Commercial License Agreement with Bayer¹
BAYER
Ⓡ®
Mirena is the #1
prescribed IUD
in the U.S.*
•Bayer received the right to obtain exclusive US rights to
commercialize the product, following completion of the
pivotal clinical trial if Bayer, in its sole discretion, pays Daré
$20 million.
•Daré may receive up to $310 million in commercial milestone
payments, plus double-digit, tiered royalties on net sales.
Bayer supports the development and regulatory process by
providing up to two full-time equivalents (internal experts) in
an advisory capacity, which gives Daré access to their global
manufacturing, regulatory, medical and commercial
expertise.
We believe the licensing agreement with Bayer is validation of our broader corporate strategy and confirmation of Ovaprene's
market potential, if approved, as the first monthly non-hormonal contraceptive product in the US market.
* https://www.mirena-us.com/; supported by 2014-2016 SHS data.
1.https://ir.darebioscience.com/news-releases/news-release-details/bayer-and-dare-bioscience-announce-exclusive-licensing-agreement
27View entire presentation